➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,976,870

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,976,870 protect, and when does it expire?

Patent 7,976,870 protects XARTEMIS XR and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 7,976,870
Title:Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Abstract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.
Inventor(s): Berner; Bret (Half Moon Bay, CA), Louie-Helm; Jenny (Fremont, CA), Shell; John W. (Hillsborough, CA)
Assignee: Depomed, Inc. (Menlo Park, CA)
Application Number:10/769,574
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,976,870
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery; Formulation;

Drugs Protected by US Patent 7,976,870

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.